Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Guangzhen Ni"'
Publikováno v:
Cancer Biomarkers. 21:513-519
Background and objective Propofol, an intravenous anesthetic agent, has been found to inhibit growth of breast cancer cells. However, the mechanisms underlying the antitumor are not known. A recent report has found that propofol could significantly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bf5226d8eb7834b776d46546a173976
https://doi.org/10.3233/cbm-170234
https://doi.org/10.3233/cbm-170234
Publikováno v:
Cancer Biomarkers. 20:469-476
MUC1, a membrane tethered mucin glycoprotein, is overexpressed in > 60% of human pancreatic cancers (PCs), and is associated with poor prognosis and enhanced metastasis. Here, we report the effect of silencing MUC1 expression on the growth, migration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa882c44e9ee825591ecf01869c58da
https://doi.org/10.3233/cbm-170297
https://doi.org/10.3233/cbm-170297
Publikováno v:
Cancer biomarkers : section A of Disease markers. 21(3)
OBJECTIVE Emerging evidence has suggested that circulating microRNAs (miRNAs) in body fluids have novel diagnostic and prognostic significance for patients with malignant diseases. The lack of useful biomarkers is a crucial problem of osteosarcoma (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37333c2cef7aa4e7d17a1badb758dd9a
https://pubmed.ncbi.nlm.nih.gov/29103020
https://pubmed.ncbi.nlm.nih.gov/29103020
Publikováno v:
Cancer biomarkers : section A of Disease markers. 20(2)
BACKGROUND AND OBJECTIVE Studies in developing animals have demonstrated that when anesthetic agents, such as propofol, are early administered in life, it can lead to neuronal cell death and learning disabilities. However, the mechanisms causing thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd93484e3bbf0deea145eb434987bcd
https://pubmed.ncbi.nlm.nih.gov/28869449
https://pubmed.ncbi.nlm.nih.gov/28869449
Publikováno v:
Cancer Biomarkers; 2017, Vol. 20 Issue 4, p469-476, 8p
Publikováno v:
Cancer Biomarkers; 2017, Vol. 20 Issue 2, p175-181, 7p
Publikováno v:
World Journal of Surgical Oncology; 2015, Vol. 13 Issue 1, p1-8, 8p
Publikováno v:
World Journal of Surgical Oncology
Background Our previous study has demonstrated that knockdown of activated ERK1/2(pERK1/2) sensitizes pancreatic cancer cells to chemotherapeutic drug gemcitabine (Gem) treatment. However, the details of this survival mechanism remain undefined. It h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::885a445519203692ea15f33375034b03